Equities research analysts predict that AngioDynamics, Inc. (NASDAQ:ANGO) will report earnings per share (EPS) of $0.17 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AngioDynamics’ earnings, with the lowest EPS estimate coming in at $0.16 and the highest estimate coming in at $0.17. AngioDynamics posted earnings per share of $0.19 during the same quarter last year, which suggests a negative year-over-year growth rate of 10.5%. The business is scheduled to announce its next earnings report on Friday, January 5th.
According to Zacks, analysts expect that AngioDynamics will report full year earnings of $0.67 per share for the current fiscal year, with EPS estimates ranging from $0.64 to $0.70. For the next year, analysts expect that the business will report earnings of $0.74 per share, with EPS estimates ranging from $0.67 to $0.81. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $85.40 million for the quarter, compared to analyst estimates of $86.12 million. AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 earnings per share.
A number of equities analysts have commented on the company. Canaccord Genuity restated a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a research note on Sunday, October 8th. Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Tuesday, October 3rd. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research note on Friday, September 29th. Finally, BidaskClub upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $18.60.
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of AngioDynamics by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 1,694,290 shares of the medical instruments supplier’s stock valued at $29,396,000 after purchasing an additional 116,814 shares during the last quarter. Morgan Stanley increased its stake in shares of AngioDynamics by 2.0% in the 1st quarter. Morgan Stanley now owns 240,773 shares of the medical instruments supplier’s stock valued at $4,176,000 after purchasing an additional 4,669 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of AngioDynamics by 67.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 234,558 shares of the medical instruments supplier’s stock valued at $4,070,000 after purchasing an additional 94,282 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of AngioDynamics by 77.5% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 3,100 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of AngioDynamics by 91.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 3,238 shares during the last quarter. Hedge funds and other institutional investors own 95.29% of the company’s stock.
AngioDynamics (NASDAQ:ANGO) traded up $0.18 during trading on Monday, reaching $17.21. The company’s stock had a trading volume of 241,604 shares, compared to its average volume of 234,013. AngioDynamics has a 12-month low of $14.80 and a 12-month high of $18.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.48 and a current ratio of 2.34. The company has a market cap of $625.27, a price-to-earnings ratio of 24.68, a PEG ratio of 1.75 and a beta of 1.04.
ILLEGAL ACTIVITY NOTICE: “$0.17 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/11/0-17-eps-expected-for-angiodynamics-inc-ango-this-quarter.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Get a free copy of the Zacks research report on AngioDynamics (ANGO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.